drug receptors
Drugs and Receptors
Most drugs act by interacting with proteins, mainly receptors (e.g., neurotransmitters and hormones).
Receptor Features:
Signal transduction capability modifying cell function.
Structure matches the ligand.
Forces in Binding (from strongest to weakest):
Covalent bonds
Ionic bonds
Hydrogen bonds
Van der Waals forces
Hydrophobic forces
Agonists and Antagonists: Affinity and Efficacy
Definitions:
Agonist: Binds and activates receptors (produces response).
Antagonist: Binds but does not activate receptors.
Response Relationships:
Response magnitude correlates with agonist concentration (hyperbolic to sigmoid on log scale).
Binding and Efficacy:
Proportion of receptors bound influences response size; EC50 denotes the concentration for 50% max response.
Competitive Antagonism
Shifts agonist response curve to the right without altering max response; requires higher agonist concentrations.
Structure-Activity Relationships
Determines potency of closely related compounds aiding in receptor classification (e.g., nicotinic vs. muscarinic receptors).
Stereochemistry in Drug Action
Different stereoisomers can have distinct potencies, affecting receptor interaction.
Radioligand Binding
Measures drug-receptor interaction through total and specific binding using radioligand.
Specific binding is determined by subtracting non-specific binding.
Quantification of Drug-Receptor Interactions
Binding Dynamics:
Drug-binding model and rate constants explain receptor occupancy.
Saturation Binding: A fraction of receptors binds to drugs; affinity constant (Ka) and dissociation constant (Kd) are derived.
Cooperativity
Two binding site effects observed in receptors (e.g., nicotinic ACh receptor).
Receptor Families
Main families include:
Intracellular receptors (small molecules).
Ligand-gated ion channels.
Receptor with intrinsic enzymatic activity.
Receptors linked to soluble kinases.
G-protein-coupled receptors (GPCRs).
G Protein-Coupled Receptors
GPCR structure: seven membrane-spanning helices.
Coupling to G proteins transduces signals based on agonist binding, affecting second messenger generation.
Agonist Bias at GPCRs
Bias Concept: Different pathways activated by various agonists leads to potential reduced side effects in drug design.
Example: TRV130 showcases reduced adverse effects compared to traditional agonists.